All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Alessandro Vannucchi, University of Florence, Florence, IT. We asked, How can chromosomal and mutation abnormalities in chronic myeloproliferative neoplasms (MPN) inform clinical decision making?
How can chromosomal and mutation abnormalities in chronic MPN inform clinical decision making?
Vannucchi opens by outlining the history of the discovery of gene mutations within MPN that have led to the development of the three classes of driver mutations: JAK2, MPL, and CALR. Vannucchi continues by discussing the recent developments and improvements in scoring criteria methods and considers the applications of these two factors in combination for patients with primary myelofibrosis. Vannucchi concludes that with improved scoring systems and the addition of novel molecular values, this can allow for patients to be better stratified within risk categories.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee have provided their recommendations for the...
Mutations in JAK2, CALR, and MPL and the effect on response to IFNα in MPN
Classical BCR-ABL1-negative myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET), are typically...
Subscribe to get the best content related to MPN delivered to your inbox